A protective effect of Ivermectin on vasculitis rat model: Histopathological study.
DOI:
https://doi.org/10.32947/ajps.v25i4.1220Keywords:
Vasculitis, Ivermectin, histopathological evaluation, alveolar destruction, vascular congestion and dilatationAbstract
Vasculitis is an inflammation in the blood vessel wall, with variation in severity and the system affected. Vasculitis pathogenesis is caused by three possible mechanisms, including autoantibodies anti-neutrophil cytoplasmic antibodies, activation of T lymphocyte cells, and immune complexes.Various pathogens stimulate innate and adaptive immune systems, modulating the expression of pro-inflammatory cells, cytokines, and the complement system, that have a role in vasculitis progression. Ivermectin is an anti-parasitic drug, effective in treating parasitic infections. Thirty-three male albino rats were used for the experiment and divided into five groups. The disease was induced in all groups except group A (control), rats received the vehicles used in dissolving drug and chemicals. Group B (induction group) received Ovalbumin and Lipopolysaccharide. Group C, group D, and group E (Ivermectin groups) received 0.5mg/kg, 1 mg/kg and 1.5 mg/kg of Ivermectin, respectively, for seven days. All doses were injected by intraperitoneal route. Results of histopathological evaluation of lung sections of Ivermectin groups show a decrease in the inflammation severity, alveolar destruction, and vascular congestion and dilatation, with the absence of: hemorrhage, thrombi, and fibrinoid wall necrosis in comparison to the disease group. Therefore, the Ivermectin drug might have a protective effect against vasculitis.
References
1- Jatwani S, Goyal A. Vasculitis. StatPearls. [Updated 2023 Aug 8]; 2024.
2- Watts RA, Hatemi G, Burns JC, Mohammad AJ. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022 Jan 1;18(1):22–34.
3- Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Cellular Signaling Pathways in Medium and Large Vessel Vasculitis. Front Immunol. 2020 Sep 25;11:587089.
4- Massicotte-Azarniouch D, Herrera CA, Jennette JC, Falk RJ, Free ME. Mechanisms of vascular damage in ANCA vasculitis. Semin Immunopathol. 2022 May 7;44(3):325–45.
5- Omar Mustafa Alghulami, Ghaith A. Jasim, Suzan Yousif Jasim**. Histopathological evaluation of docetaxel effects in treatment of rheumatoid arthritis induced in rat model. Al Mustansiriyah J Pharm Sci. 2023 May 22;23(2):168–79.
6- Assim Oday Farooq, Nadia Hameed Mohammed. Effect of Captopril on Toll Like Receptor Expression in Adjuvant Induced Arthritis. Al Mustansiriyah J Pharm Sci. 2022 Jul 4;22(1):1–7.
7- Villar-Fincheira P, Sanhueza-Olivares F, Norambuena-Soto I, Cancino-Arenas N, Hernandez-Vargas F, Troncoso R, et al. Role of Interleukin-6 in Vascular Health and Disease. Front Mol Biosci. 2021 Mar 16;8:641734.
8- Teixeira BC, Lopes AL, Macedo RCO, Correa CS, Ramis TR, Ribeiro JL, et al. Inflammatory markers, endothelial function and cardiovascular risk. J Vasc Bras. 2014 Apr;13(2):108–15.
9- Makhzoum JP, Grayson PC, Ponte C, Robson J, Suppiah R, Watts RA, et al. Pulmonary involvement in primary systemic vasculitides. Rheumatology. 2021 Dec 24;61(1):319–30.
10- de Souza DK, Thomas R, Bradley J, Leyrat C, Boakye DA, Okebe J. Ivermectin treatment in humans for reducing malaria transmission. Cochrane database Syst Rev. 2021 Jun 29;6(6):CD013117.
11- Martin RJ, Robertson AP, Choudhary S. Ivermectin: An Anthelmintic, an Insecticide, and Much More. Trends Parasitol. 2021 Jan;37(1):48–64.
12- Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun 1;178:104787.
13- Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021 Feb;103:214–6.
14- Kern C, Müller P, Chaccour C, Liechti ME, Hammann F, Duthaler U. Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes. Malar J. 2023 Jun 24;22(1):194.
15- TRAILOVIC SM, NEDELJKOVIC JT. Central and Peripheral Neurotoxic Effects of Ivermectin in Rats. J Vet Med Sci. 2011;73(5):591–9.
16- Zainal Z, Abdul Rahim A, Khaza’ai H, Chang SK. Effects of Palm Oil Tocotrienol-Rich Fraction (TRF) and Carotenes in Ovalbumin (OVA)-Challenged Asthmatic Brown Norway Rats. Int J Mol Sci. 2019 Apr 10;20(7):1764.
17- Mohamed HA, Elbastawisy YM, Elsaed WM. Attenuation of lipopolysaccharide-induced lung inflammation by ascorbic acid in rats: Histopathological and ultrastructural study. SAGE Open Med. 2019 Jan 4;7:205031211982826.
18- Thakur VR, Mehta AA. Ovalbumin/lipopolysaccharide induced vasculitis in rats: a new predictive model. J Basic Clin Physiol Pharmacol. 2022 Aug 9;33(4):445–55.
19- Struck MB, Andrutis KA, Ramirez HE, Battles AH. Effect of a short-term fast on ketamine-xylazine anesthesia in rats. J Am Assoc Lab Anim Sci. 2011 May;50(3):344–8.
20- Yaqeen Talib Mohammed, Nadia Hameed Mohammed, Inam Sameh Arif. The Potential Effect of Simvastatin on Regulatory T cells in Experimentally Induced Autoimmune Thyroiditis in Female Rats. Al Mustansiriyah J Pharm Sci. 2023 Oct 9;23(4):443–53.
21- Argun Baris S, Vural C, Yaprak B, Onyilmaz T, Tuncel D, Vatansever S, et al. The effects of sildenafil on smoke induced lung inflammation in rats. Malays J Pathol. 2016 Apr;38(1):39–44.
22- 22. Zhang X, Song Y, Ci X, An N, Ju Y, Li H, et al. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res. 2008 Nov 13;57(11):524–9.
23- Ma Y, Xu X, Wu H, Li C, Zhong P, Liu Z, et al. Ivermectin contributes to attenuating the severity of acute lung injury in mice. Biomed Pharmacother. 2022 Nov 1;155:113706.
24- Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review. J Antibiot (Tokyo). 2022 Feb 21;75(2):60–71.
25- Petrache I, Serban K. Emphysema. In: Pathobiology of Human Disease. Elsevier; 2014. p. 2609–24.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Teeba Sarem Sadeq, Nadia Hameed Mohammed, Inam Sameh Arif, Sayed Mahmood Alqallaf
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
